0001140361-18-013111.txt : 20180312 0001140361-18-013111.hdr.sgml : 20180312 20180312182634 ACCESSION NUMBER: 0001140361-18-013111 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180308 FILED AS OF DATE: 20180312 DATE AS OF CHANGE: 20180312 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wilson Kenneth W. CENTRAL INDEX KEY: 0001530777 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10670 FILM NUMBER: 18684748 MAIL ADDRESS: STREET 1: 10910 DOMAIN DRIVE, SUITE 300 CITY: AUSTIN STATE: TX ZIP: 78758 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: HANGER, INC. CENTRAL INDEX KEY: 0000722723 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC [8093] IRS NUMBER: 840904275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10910 DOMAIN DRIVE STREET 2: SUITE 300 CITY: AUSTIN STATE: TX ZIP: 78758 BUSINESS PHONE: 512-777-3800 MAIL ADDRESS: STREET 1: 10910 DOMAIN DRIVE STREET 2: SUITE 300 CITY: AUSTIN STATE: TX ZIP: 78758 FORMER COMPANY: FORMER CONFORMED NAME: HANGER ORTHOPEDIC GROUP INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: SEQUEL CORP DATE OF NAME CHANGE: 19890814 FORMER COMPANY: FORMER CONFORMED NAME: CELLTECH COMMUNICATIONS INC DATE OF NAME CHANGE: 19860304 4 1 doc1.xml FORM 4 X0306 4 2018-03-08 0 0000722723 HANGER, INC. HGR 0001530777 Wilson Kenneth W. 10910 DOMAIN DRIVE, SUITE 300 AUSTIN TX 78758 0 1 0 0 Pres./COO Southern Prosthetic* Common Stock 2018-03-08 4 F 0 670 15.70 D 57914 D Common Stock 2018-03-09 4 A 0 10351 0 A 68265 D Stock Options (right to buy) 12.77 2027-05-19 Common Stock 54834 54834 D Performance Share Units 2020-05-19 Common Stock 21934 21934 D Reflects payment of tax liability by withholding shares of stock incident to vesting of restricted stock previously issued. Represents a grant of time-based restricted stock under the Company's 2016 Omnibus Incentive Plan ("Plan"), which vests to the extent of 25% annually beginning on March 9, 2019 and cumulatively vests to the extent of 25% each year thereafter. The restricted stock being reported does not include the contingent right of the reporting person to receive up to 10,351 additional performance shares under the Plan based on the achievement of certain performance targets for the fiscal year 2018. Includes (i) unvested restricted shares totaling 10,351 shares of stock from an initial grant of 10,351 shares of restricted stock that begins to vest on March 9, 2019; (ii) unvested restricted shares and fully vested shares totaling 7,561 shares of stock from an initial grant of 9,539 shares of restricted stock, half of which vested on January 25, 2018 and the remainder of which will vest on March 6, 2018 and 2019; (iii) unvested restricted shares which total 10,330 shares of stock from an initial grant of 11,000 shares of restricted stock that begins to vest on March 8, 2018; (iv) unvested restricted shares and fully vested shares totaling 4,658 shares of stock from an initial grant of 5,000 shares of restricted stock that begins to vest on October 11, 2017; (v) unvested restricted shares and fully vested shares totaling 9,485 shares of stock from an initial grant of 11,000 shares of restricted stock that begins to vest on March 7, 2017; [continued in next footnote] (vi) unvested restricted shares and fully vested shares totaling 4,947 shares of stock from an initial grant of 6,359 shares of restricted stock made on March 6, 2015; (vii) fully vested shares totaling 2,839 shares of stock from an initial grant of 3,661 shares of restricted stock made on March 7, 2014; (viii) fully vested shares totaling 5,839 shares of stock from an initial grant of 8,075 shares of restricted stock and performance shares made on March 11, 2013; (ix) fully vested shares totaling 6,833 shares of stock from an initial grant of 13,800 shares of restricted stock and performance shares made on March 7, 2012 and (x) fully vested shares totaling 5,422 shares of stock from an initial grant of 15,000 shares of restricted stock made on September 19, 2011. Except as otherwise noted, all remaining unvested restricted shares will continue to vest at a rate of 25% per year of the original grant amount on the anniversary date of the grant. Stock options were granted under the Company's Special Equity Plan and vest 1/3 on each of May 19, 2018, 2019 and 2020. Performance share units ("PSUs") were granted under the Company's Special Equity Plan. Each PSU represents a contingent right to receive one share of common stock if predetermined levels of absolute common stock price compounded annual growth rate are achieved over a three-year performance period ending on the third anniversary of the grant date. The number of PSUs shown in the table represents the maximum number that could be earned; the target number is one-half the maximum number. * President and Chief Operating Officer of Southern Prosthetic Supply, Inc. /s/ Jessica Lochmann Allen, Attorney-in-Fact for Kenneth W. Wilson 2018-03-12